Tag: oncology
Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma
Neel Mistry -0
1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months).
2. Occurrence of grade 3 or 4 adverse events were similar among patients in the cabozantinib and sunitinib groups.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Papillary renal cell carcinoma (PRCC) is...
Low and middle-income countries show greater post-operative mortality following cancer surgery
Michael Pratte -
1. Low- and middle-income countries have a higher 30-day mortality in colorectal and gastric cancer surgeries compared with high-income countries.
2. Although the rate of peri-operative complications was similar across all country income levels, patients in low or lower-middle income countries were more likely to die from these events.
Evidence Rating...